Recent SEC filings indicate significant insider buying, with Gary W. Pace acquiring 290,000 shares of Cardiff Oncology (CRDF) for $710,500 at $2.45 each, preceding a 14.6% gain for CRDF on Friday. Separately, Merchants Bancorp (MBIN) CEO Michael R. Dury purchased 16,000 shares for $504,936 at $31.56, adding to prior investments, even as MBIN traded as much as 8.9% below his latest price on Friday, potentially signaling a value opportunity for other investors despite the stock's modest 0.3% daily gain.
Significant insider buying activity has been reported at two distinct companies, yielding disparate market reactions. At Cardiff Oncology (CRDF), a single purchase of 290,000 shares by Gary W. Pace for $710,500 at $2.45 per share was followed by a strong 14.6% increase in the stock price by Friday, indicating the market perceived this as a high-impact, bullish signal. Conversely, at Merchants Bancorp (MBIN), CEO Michael R. Dury's purchase of $504,936 worth of stock at $31.56 per share, his fifth such purchase in the past year, did not elicit a similar response. MBIN's stock saw a muted 0.3% gain and traded as much as 8.9% below the CEO's entry price. This divergence suggests that while the CEO's repeated buys signal strong internal confidence in MBIN's value, the market has not yet priced in this conviction, potentially due to external factors or a lag in recognizing the underlying thesis.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
